CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein.
Identifieur interne : 002191 ( Ncbi/Merge ); précédent : 002190; suivant : 002192CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein.
Auteurs : Kai Zhao [République populaire de Chine] ; Binyan Yang ; Yanquan Xu ; Changyou WuSource :
- Vaccine [ 1873-2518 ] ; 2010.
Descripteurs français
- KwdFr :
- ADN viral (immunologie), Animaux, Antigène HLA-A2, Antigènes HLA-A, Déterminants antigéniques des lymphocytes T (immunologie), Facteur de nécrose tumorale alpha (immunologie), Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Immunité cellulaire, Interféron gamma (immunologie), Interleukine-2 (immunologie), Lymphocytes T CD8+ (immunologie), Mémoire immunologique, Protéines de l'enveloppe virale (immunologie), Souris, Souris transgéniques, Syndrome respiratoire aigu sévère (immunologie), Vaccins antiviraux (immunologie), Vaccins à ADN (immunologie), Virus du SRAS (immunologie).
- MESH :
- immunologie : ADN viral, Déterminants antigéniques des lymphocytes T, Facteur de nécrose tumorale alpha, Glycoprotéines membranaires, Interféron gamma, Interleukine-2, Lymphocytes T CD8+, Protéines de l'enveloppe virale, Syndrome respiratoire aigu sévère, Vaccins antiviraux, Vaccins à ADN, Virus du SRAS.
- Animaux, Antigène HLA-A2, Antigènes HLA-A, Glycoprotéine de spicule des coronavirus, Immunité cellulaire, Mémoire immunologique, Souris, Souris transgéniques.
English descriptors
- KwdEn :
- Animals, CD8-Positive T-Lymphocytes (immunology), DNA, Viral (immunology), Epitopes, T-Lymphocyte (immunology), HLA-A Antigens, HLA-A2 Antigen, Immunity, Cellular, Immunologic Memory, Interferon-gamma (immunology), Interleukin-2 (immunology), Membrane Glycoproteins (immunology), Mice, Mice, Transgenic, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus, Tumor Necrosis Factor-alpha (immunology), Vaccines, DNA (immunology), Viral Envelope Proteins (immunology), Viral Vaccines (immunology).
- MESH :
- chemical , immunology : DNA, Viral, Epitopes, T-Lymphocyte, Interferon-gamma, Interleukin-2, Membrane Glycoproteins, Tumor Necrosis Factor-alpha, Vaccines, DNA, Viral Envelope Proteins, Viral Vaccines.
- immunology : CD8-Positive T-Lymphocytes, SARS Virus, Severe Acute Respiratory Syndrome.
- Animals, HLA-A Antigens, HLA-A2 Antigen, Immunity, Cellular, Immunologic Memory, Mice, Mice, Transgenic, Spike Glycoprotein, Coronavirus.
Abstract
Cytotoxic CD8(+) T lymphocytes (CTLs) play an important role in antiviral immunity. Several human HLA-A*0201 restricted CTL epitopes of severe acute respiratory syndrome (SARS) spike (S) protein have been identified in HLA-A*0201 transgenic (Tg) mice, but the mechanisms and properties of immune responses are still not well understood. In this study, HLA-A*0201 Tg mice were primed intramuscularly with SARS S DNA and boosted subcutaneously with HLA-A*0201 restricted peptides. The lymphocytes from draining lymph nodes, spleens and lungs were stimulated with the cognate peptides. Three different methods (ELISA, ELISPOT and FACS) were used to evaluate the immune responses during short and long periods of time after immunization. Results showed that peptide-specific CD8(+) T cells secreted IFN-γ, TNF-α and IL-2 and expressed CD107a/b on cell surface. IFN-γ(+)CD8(+) T cells and CD107a/b(+)CD8(+) T cells distributed throughout the lymphoid and non-lymphoid tissues, but the frequency of peptide-specific CD8(+) T cells was higher in lungs than in spleens and lymph nodes. The phenotype of the CD8(+) T cells was characterized based on the expression of IFN-γ. Most of the HLA-A*0201 restricted peptide-specific CD8(+) T cells represented a memory subset with CD45RB(high) and CD62L(low). Taken together, these data demonstrate that immunization with SARS S DNA and HLA-A*0201 restricted peptides can elicit antigen-specific CD8(+) T cell immune responses which may have a significant implication in the long-term protection. We provide novel information in cellular immune responses of SARS S antigen-specific CD8(+) T cells, which are important in the development of vaccine against SARS-CoV infection.
DOI: 10.1016/j.vaccine.2010.08.013
PubMed: 20709007
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001648
- to stream PubMed, to step Curation: 001648
- to stream PubMed, to step Checkpoint: 001704
Links to Exploration step
pubmed:20709007Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein.</title><author><name sortKey="Zhao, Kai" sort="Zhao, Kai" uniqKey="Zhao K" first="Kai" last="Zhao">Kai Zhao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080, People' s Republic of China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080</wicri:regionArea><wicri:noRegion>Guangdong Province 510080</wicri:noRegion></affiliation></author><author><name sortKey="Yang, Binyan" sort="Yang, Binyan" uniqKey="Yang B" first="Binyan" last="Yang">Binyan Yang</name></author><author><name sortKey="Xu, Yanquan" sort="Xu, Yanquan" uniqKey="Xu Y" first="Yanquan" last="Xu">Yanquan Xu</name></author><author><name sortKey="Wu, Changyou" sort="Wu, Changyou" uniqKey="Wu C" first="Changyou" last="Wu">Changyou Wu</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20709007</idno><idno type="pmid">20709007</idno><idno type="doi">10.1016/j.vaccine.2010.08.013</idno><idno type="wicri:Area/PubMed/Corpus">001648</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001648</idno><idno type="wicri:Area/PubMed/Curation">001648</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001648</idno><idno type="wicri:Area/PubMed/Checkpoint">001704</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001704</idno><idno type="wicri:Area/Ncbi/Merge">002191</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein.</title><author><name sortKey="Zhao, Kai" sort="Zhao, Kai" uniqKey="Zhao K" first="Kai" last="Zhao">Kai Zhao</name><affiliation wicri:level="1"><nlm:affiliation>Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080, People' s Republic of China.</nlm:affiliation><country xml:lang="fr" wicri:curation="lc">République populaire de Chine</country><wicri:regionArea>Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080</wicri:regionArea><wicri:noRegion>Guangdong Province 510080</wicri:noRegion></affiliation></author><author><name sortKey="Yang, Binyan" sort="Yang, Binyan" uniqKey="Yang B" first="Binyan" last="Yang">Binyan Yang</name></author><author><name sortKey="Xu, Yanquan" sort="Xu, Yanquan" uniqKey="Xu Y" first="Yanquan" last="Xu">Yanquan Xu</name></author><author><name sortKey="Wu, Changyou" sort="Wu, Changyou" uniqKey="Wu C" first="Changyou" last="Wu">Changyou Wu</name></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>CD8-Positive T-Lymphocytes (immunology)</term><term>DNA, Viral (immunology)</term><term>Epitopes, T-Lymphocyte (immunology)</term><term>HLA-A Antigens</term><term>HLA-A2 Antigen</term><term>Immunity, Cellular</term><term>Immunologic Memory</term><term>Interferon-gamma (immunology)</term><term>Interleukin-2 (immunology)</term><term>Membrane Glycoproteins (immunology)</term><term>Mice</term><term>Mice, Transgenic</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Tumor Necrosis Factor-alpha (immunology)</term><term>Vaccines, DNA (immunology)</term><term>Viral Envelope Proteins (immunology)</term><term>Viral Vaccines (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>ADN viral (immunologie)</term><term>Animaux</term><term>Antigène HLA-A2</term><term>Antigènes HLA-A</term><term>Déterminants antigéniques des lymphocytes T (immunologie)</term><term>Facteur de nécrose tumorale alpha (immunologie)</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires (immunologie)</term><term>Immunité cellulaire</term><term>Interféron gamma (immunologie)</term><term>Interleukine-2 (immunologie)</term><term>Lymphocytes T CD8+ (immunologie)</term><term>Mémoire immunologique</term><term>Protéines de l'enveloppe virale (immunologie)</term><term>Souris</term><term>Souris transgéniques</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins antiviraux (immunologie)</term><term>Vaccins à ADN (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>DNA, Viral</term><term>Epitopes, T-Lymphocyte</term><term>Interferon-gamma</term><term>Interleukin-2</term><term>Membrane Glycoproteins</term><term>Tumor Necrosis Factor-alpha</term><term>Vaccines, DNA</term><term>Viral Envelope Proteins</term><term>Viral Vaccines</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>ADN viral</term><term>Déterminants antigéniques des lymphocytes T</term><term>Facteur de nécrose tumorale alpha</term><term>Glycoprotéines membranaires</term><term>Interféron gamma</term><term>Interleukine-2</term><term>Lymphocytes T CD8+</term><term>Protéines de l'enveloppe virale</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins antiviraux</term><term>Vaccins à ADN</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>CD8-Positive T-Lymphocytes</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>HLA-A Antigens</term><term>HLA-A2 Antigen</term><term>Immunity, Cellular</term><term>Immunologic Memory</term><term>Mice</term><term>Mice, Transgenic</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Antigène HLA-A2</term><term>Antigènes HLA-A</term><term>Glycoprotéine de spicule des coronavirus</term><term>Immunité cellulaire</term><term>Mémoire immunologique</term><term>Souris</term><term>Souris transgéniques</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cytotoxic CD8(+) T lymphocytes (CTLs) play an important role in antiviral immunity. Several human HLA-A*0201 restricted CTL epitopes of severe acute respiratory syndrome (SARS) spike (S) protein have been identified in HLA-A*0201 transgenic (Tg) mice, but the mechanisms and properties of immune responses are still not well understood. In this study, HLA-A*0201 Tg mice were primed intramuscularly with SARS S DNA and boosted subcutaneously with HLA-A*0201 restricted peptides. The lymphocytes from draining lymph nodes, spleens and lungs were stimulated with the cognate peptides. Three different methods (ELISA, ELISPOT and FACS) were used to evaluate the immune responses during short and long periods of time after immunization. Results showed that peptide-specific CD8(+) T cells secreted IFN-γ, TNF-α and IL-2 and expressed CD107a/b on cell surface. IFN-γ(+)CD8(+) T cells and CD107a/b(+)CD8(+) T cells distributed throughout the lymphoid and non-lymphoid tissues, but the frequency of peptide-specific CD8(+) T cells was higher in lungs than in spleens and lymph nodes. The phenotype of the CD8(+) T cells was characterized based on the expression of IFN-γ. Most of the HLA-A*0201 restricted peptide-specific CD8(+) T cells represented a memory subset with CD45RB(high) and CD62L(low). Taken together, these data demonstrate that immunization with SARS S DNA and HLA-A*0201 restricted peptides can elicit antigen-specific CD8(+) T cell immune responses which may have a significant implication in the long-term protection. We provide novel information in cellular immune responses of SARS S antigen-specific CD8(+) T cells, which are important in the development of vaccine against SARS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20709007</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>28</Volume><Issue>41</Issue><PubDate><Year>2010</Year><Month>Sep</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein.</ArticleTitle><Pagination><MedlinePgn>6666-74</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2010.08.013</ELocationID><Abstract><AbstractText>Cytotoxic CD8(+) T lymphocytes (CTLs) play an important role in antiviral immunity. Several human HLA-A*0201 restricted CTL epitopes of severe acute respiratory syndrome (SARS) spike (S) protein have been identified in HLA-A*0201 transgenic (Tg) mice, but the mechanisms and properties of immune responses are still not well understood. In this study, HLA-A*0201 Tg mice were primed intramuscularly with SARS S DNA and boosted subcutaneously with HLA-A*0201 restricted peptides. The lymphocytes from draining lymph nodes, spleens and lungs were stimulated with the cognate peptides. Three different methods (ELISA, ELISPOT and FACS) were used to evaluate the immune responses during short and long periods of time after immunization. Results showed that peptide-specific CD8(+) T cells secreted IFN-γ, TNF-α and IL-2 and expressed CD107a/b on cell surface. IFN-γ(+)CD8(+) T cells and CD107a/b(+)CD8(+) T cells distributed throughout the lymphoid and non-lymphoid tissues, but the frequency of peptide-specific CD8(+) T cells was higher in lungs than in spleens and lymph nodes. The phenotype of the CD8(+) T cells was characterized based on the expression of IFN-γ. Most of the HLA-A*0201 restricted peptide-specific CD8(+) T cells represented a memory subset with CD45RB(high) and CD62L(low). Taken together, these data demonstrate that immunization with SARS S DNA and HLA-A*0201 restricted peptides can elicit antigen-specific CD8(+) T cell immune responses which may have a significant implication in the long-term protection. We provide novel information in cellular immune responses of SARS S antigen-specific CD8(+) T cells, which are important in the development of vaccine against SARS-CoV infection.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, 74 Zhongshan 2nd Road, Guangzhou, Guangdong Province 510080, People' s Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Binyan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yanquan</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Changyou</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004279">DNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015234">HLA-A Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C435939">HLA-A*02:01 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015789">HLA-A2 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004279" MajorTopicYN="N">DNA, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015234" MajorTopicYN="N">HLA-A Antigens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015789" MajorTopicYN="N">HLA-A2 Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007111" MajorTopicYN="N">Immunity, Cellular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20709007</ArticleId><ArticleId IdType="pii">S0264-410X(10)01122-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2010.08.013</ArticleId><ArticleId IdType="pmc">PMC7115361</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 2006 Feb;80(4):2034-44</Citation><ArticleIdList><ArticleId IdType="pubmed">16439559</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 2002 Sep;32(9):2562-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12207340</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunol Today. 1996 Jun;17(6):261-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8962628</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2006 May 26;344(1):63-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16630549</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1997 Oct;71(10):7889-94</Citation><ArticleIdList><ArticleId IdType="pubmed">9311878</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 2003 Feb 15;306(2):376-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12642110</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2006 Aug 15;177(4):2138-45</Citation><ArticleIdList><ArticleId IdType="pubmed">16887973</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2007 Sep 28;25(39-40):6981-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17709158</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2004 Apr 15;172(8):4875-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15067066</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Virol. 2008 Feb;80(2):225-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18098130</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2004 Feb;4(2):64</Citation><ArticleIdList><ArticleId IdType="pubmed">14959754</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Eur J Immunol. 2002 Aug;32(8):2117-23</Citation><ArticleIdList><ArticleId IdType="pubmed">12209623</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1999 Apr 1;162(7):3915-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10201910</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2005 Apr 15;23(21):2801-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15780728</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet Infect Dis. 2004 Feb;4(2):64</Citation><ArticleIdList><ArticleId IdType="pubmed">14959753</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(11):5535-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15140950</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Blood. 2004 Jul 1;104(1):200-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15016646</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Immunol. 2006 Aug;120(2):171-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16781892</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1998 Dec 1;161(11):6238-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9834111</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 2004 Apr 5;199(7):925-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15051762</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Bull World Health Organ. 2004 Feb;82(2):152-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15042239</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Immunol. 2009 Dec 03;10:61</Citation><ArticleIdList><ArticleId IdType="pubmed">19958537</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Blood. 2002 Mar 15;99(6):2100-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11877285</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9804-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15210961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Jun;78(12):6134-42</Citation><ArticleIdList><ArticleId IdType="pubmed">15163706</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol Methods. 2003 Oct 1;281(1-2):65-78</Citation><ArticleIdList><ArticleId IdType="pubmed">14580882</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2003 Aug 15;171(4):2024-34</Citation><ArticleIdList><ArticleId IdType="pubmed">12902507</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2004 Apr 30;304(5671):659-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15118129</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2000 Jan 4;97(1):297-302</Citation><ArticleIdList><ArticleId IdType="pubmed">10618412</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 1995 Oct 1;155(7):3443-52</Citation><ArticleIdList><ArticleId IdType="pubmed">7561039</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Immunogenetics. 1999 Nov;50(3-4):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10602881</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2004 Aug 19;351(8):827-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15317899</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2006 Nov 1;177(9):6361-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17056567</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Exp Med. 1996 Apr 1;183(4):1367-75</Citation><ArticleIdList><ArticleId IdType="pubmed">8666895</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 2006 Jun 5;24(23):4905-13</Citation><ArticleIdList><ArticleId IdType="pubmed">16621188</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>BMC Med Genet. 2003 Sep 12;4:9</Citation><ArticleIdList><ArticleId IdType="pubmed">12969506</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Wu, Changyou" sort="Wu, Changyou" uniqKey="Wu C" first="Changyou" last="Wu">Changyou Wu</name><name sortKey="Xu, Yanquan" sort="Xu, Yanquan" uniqKey="Xu Y" first="Yanquan" last="Xu">Yanquan Xu</name><name sortKey="Yang, Binyan" sort="Yang, Binyan" uniqKey="Yang B" first="Binyan" last="Yang">Binyan Yang</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Zhao, Kai" sort="Zhao, Kai" uniqKey="Zhao K" first="Kai" last="Zhao">Kai Zhao</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002191 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002191 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:20709007
|texte= CD8+ T cell response in HLA-A*0201 transgenic mice is elicited by epitopes from SARS-CoV S protein.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:20709007" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |